CN108174603B - 作为gpr52调节剂的1-杂芳基-二氢吲哚-4-甲酰胺 - Google Patents

作为gpr52调节剂的1-杂芳基-二氢吲哚-4-甲酰胺 Download PDF

Info

Publication number
CN108174603B
CN108174603B CN201680038190.3A CN201680038190A CN108174603B CN 108174603 B CN108174603 B CN 108174603B CN 201680038190 A CN201680038190 A CN 201680038190A CN 108174603 B CN108174603 B CN 108174603B
Authority
CN
China
Prior art keywords
pyridin
indoline
carboxamide
fluoro
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680038190.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108174603A (zh
Inventor
Y·熊
A·J·格勒蒂克
H·科曼
J·莱曼
A·S·任
G·森普尔
D·J·C·巴尼奥尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CN108174603A publication Critical patent/CN108174603A/zh
Application granted granted Critical
Publication of CN108174603B publication Critical patent/CN108174603B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN201680038190.3A 2015-04-29 2016-04-29 作为gpr52调节剂的1-杂芳基-二氢吲哚-4-甲酰胺 Active CN108174603B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154523P 2015-04-29 2015-04-29
US62/154,523 2015-04-29
PCT/US2016/030105 WO2016176571A1 (en) 2015-04-29 2016-04-29 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto

Publications (2)

Publication Number Publication Date
CN108174603A CN108174603A (zh) 2018-06-15
CN108174603B true CN108174603B (zh) 2021-07-02

Family

ID=56015108

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680038190.3A Active CN108174603B (zh) 2015-04-29 2016-04-29 作为gpr52调节剂的1-杂芳基-二氢吲哚-4-甲酰胺

Country Status (15)

Country Link
US (1) US9676758B2 (https=)
EP (1) EP3292114B1 (https=)
JP (1) JP6673939B2 (https=)
KR (1) KR20180004193A (https=)
CN (1) CN108174603B (https=)
AU (1) AU2016255510A1 (https=)
BR (1) BR112017022987A2 (https=)
CA (1) CA2984153A1 (https=)
CL (1) CL2017002738A1 (https=)
EA (1) EA034244B1 (https=)
ES (1) ES2784316T3 (https=)
IL (1) IL255185A0 (https=)
MX (1) MX373876B (https=)
PH (1) PH12017501961A1 (https=)
WO (1) WO2016176571A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111792990A (zh) * 2019-04-09 2020-10-20 中国科学院上海药物研究所 一种不饱和酮类化合物、其制备方法和用途
AU2020381168A1 (en) * 2019-11-08 2022-04-14 Nxera Pharma Uk Limited GPR52 modulator compounds
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds
BR112022018996A2 (pt) * 2020-03-30 2022-11-01 Boehringer Ingelheim Int 3-fenoxiazetidin-1-il-pirazinas substituídas apresentando atividade agonística do gpr52".
WO2021216705A1 (en) * 2020-04-22 2021-10-28 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
GB202013558D0 (en) 2020-08-28 2020-10-14 Heptares Therapeutics Ltd GRP52 Modularor compounds
WO2022232017A1 (en) 2021-04-26 2022-11-03 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
JP2024533565A (ja) 2021-09-14 2024-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ３－フェノキシアゼチジン－１－イル－ヘテロアリールピロリジン誘導体及び医薬としてのその使用
GB202113186D0 (en) 2021-09-15 2021-10-27 Heptares Therapeutics Ltd GPR52 Modulator compounds
WO2024091542A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
WO2024091541A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
AR130864A1 (es) * 2022-10-26 2025-01-29 Neurocrine Biosciences Inc Compuestos y composiciones como moduladores de gpr52

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2253618A1 (en) * 2008-02-27 2010-11-24 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
WO2010149685A1 (en) * 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
EP2298731A1 (en) * 2008-06-25 2011-03-23 Takeda Pharmaceutical Company Limited Amide compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2043744A2 (en) * 2006-07-13 2009-04-08 SmithKline Beecham Corporation Chemical compounds
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
TW201010977A (en) 2008-08-12 2010-03-16 Takeda Pharmaceutical Amide compound
JP2012082175A (ja) * 2010-10-14 2012-04-26 Daiichi Sankyo Co Ltd インドリン化合物を含有する医薬組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2253618A1 (en) * 2008-02-27 2010-11-24 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
EP2298731A1 (en) * 2008-06-25 2011-03-23 Takeda Pharmaceutical Company Limited Amide compound
WO2010149685A1 (en) * 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto

Also Published As

Publication number Publication date
EA034244B1 (ru) 2020-01-21
IL255185A0 (en) 2017-12-31
US20160318911A1 (en) 2016-11-03
EP3292114A1 (en) 2018-03-14
CA2984153A1 (en) 2016-11-03
EP3292114B1 (en) 2020-03-11
AU2016255510A1 (en) 2017-11-23
US9676758B2 (en) 2017-06-13
JP6673939B2 (ja) 2020-04-01
MX2017013853A (es) 2018-06-07
WO2016176571A1 (en) 2016-11-03
CL2017002738A1 (es) 2018-06-01
KR20180004193A (ko) 2018-01-10
ES2784316T3 (es) 2020-09-24
JP2018519253A (ja) 2018-07-19
BR112017022987A2 (pt) 2018-07-24
CN108174603A (zh) 2018-06-15
EA201792375A1 (ru) 2018-05-31
PH12017501961A1 (en) 2018-03-26
MX373876B (es) 2020-03-26

Similar Documents

Publication Publication Date Title
CN108174603B (zh) 作为gpr52调节剂的1-杂芳基-二氢吲哚-4-甲酰胺
EP2491024B1 (en) Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
JP2019529490A (ja) 嚢胞性線維症膜コンダクタンス制御因子の調節因子、医薬組成物、処置の方法、及び当該調節因子を作製するためのプロセス
EA028046B1 (ru) Производные бензимидазол-пролина
EP2678315B1 (en) (Pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR
CN102112476A (zh) 糖皮质激素模拟物、其制备方法、药物组合物及其用途
JP2021514963A (ja) ニューロトロフィンに関連する疾患を治療するためのトリアジン誘導体
US8372847B2 (en) Pyrazinone modulator of corticotropin-releasing factor receptor activity
CN118019533A (zh) 用于治疗中枢神经系统疾病的作为分拣蛋白调节剂的2-氨基-5,5-二甲基己酸衍生物
KR20220118483A (ko) Oga 억제제 화합물
TWI564300B (zh) 經取代之［（５Ｈ－吡咯［２，１－ｃ］［１，４］苯二氮呯－１１－基）哌嗪－１－基］－２，２－二甲基丙酸化合物作為雙重活性Ｈ１反向促進劑／５－ＨＴ2Ａ拮抗劑
TW202116755A (zh) 可用為幾丁質酶抑制劑的經取代的胺基三唑
US20130252943A1 (en) Bicyclic oxazole lactams as allosteric modulators of mglur5 receptors
CN102612515A (zh) 2-氨基-9-[4-(4-甲氧基-苯氧基)-哌啶-1-基]-4-苯基-茚并[1，2-D]嘧啶-5-酮及其作为高选择性腺苷A2a受体拮抗剂的用途
TW202442226A (zh) 化合物
JP6100400B2 (ja) 二重活性Ｈ１インバースアゴニスト／５−ＨＴ２Ａアンタゴニストとしての（チエノ［２，３−ｂ］［１，５］ベンゾオキサゼピン−４−イル）ピペラジン−１−イル化合物
HK1189222B (en) (pyridin-4-yl) benzylamides as allosteric modulators of alpha 7 nachr

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant